Q1 Earnings Estimate for Nuwellis Issued By Roth Capital

Nuwellis, Inc. (NASDAQ:NUWE) – Analysts at Roth Capital issued their Q1 2025 earnings per share estimates for Nuwellis in a research report issued to clients and investors on Monday, January 13th. Roth Capital analyst J. Aschoff expects that the company will earn ($0.30) per share for the quarter. The consensus estimate for Nuwellis’ current full-year earnings is ($9.91) per share. Roth Capital also issued estimates for Nuwellis’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.18) EPS, FY2027 earnings at $0.41 EPS and FY2029 earnings at $1.78 EPS.

Nuwellis Price Performance

NUWE stock opened at $1.05 on Wednesday. The company has a market capitalization of $4.59 million, a PE ratio of -0.01 and a beta of 0.32. Nuwellis has a 12 month low of $0.92 and a 12 month high of $27.61. The firm’s 50-day moving average is $1.29 and its 200 day moving average is $1.87.

Nuwellis (NASDAQ:NUWE) last released its earnings results on Monday, November 11th. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $2.62. The business had revenue of $2.37 million for the quarter, compared to analyst estimates of $2.40 million. Nuwellis had a negative return on equity of 28,159.25% and a negative net margin of 169.54%. During the same quarter last year, the firm posted ($63.29) earnings per share.

About Nuwellis

Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.